중추신경계(CNS) 림프종 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간의 성장은 헬스케어에 대한 환자 접근의 개선, 정부의 지원이나 이니셔티브 등의 요인에 의한 것으로 예측됩니다. 이 기간의 주요 동향으로는 진단에 있어서의 인공지능의 통합, 차세대 단클론 항체의 개발, 최소 침습 치료에의 시프트, 정밀의료의 진전, 진단 기술의 혁신 등을 들 수 있습니다.
심리장애의 발생률 증가는 중추신경계(CNS) 림프종 시장의 성장을 크게 견인할 것으로 예측됩니다. 이러한 질병의 유병률이 상승함에 따라, 뇌의 염증, 면역계의 상호작용, 혈액뇌 장벽의 이해를 깊게 하는 신경종양학 연구가 진전합니다. 예를 들어, 2024년 미국정신질환연맹(National Alliance on Mental Illness)은 18-44세 사이의 정신병 스펙트럼 및 기분 장애로 인한 입원 건수가 매년 약 60만 건에 달했다고 보고했습니다.
신경 질환의 유병률 증가는 중추신경계(CNS) 림프종 시장을 밀어 올리는 또 다른 요인입니다. 뇌, 척수, 신경에 영향을 미치는 신경질환은 유전, 감염, 외상, 독소, 자가면역반응, 변성 과정 등의 요인에 의해 보다 일반적으로 되고 있습니다. 중추신경계 림프종의 연구는 뇌 기능, 면역 반응, 신경 염증의 이해를 깊게함으로써 신경 질환의 진단과 치료의 진보에 크게 기여하고 있습니다. 예를 들어, 2022년 4월 유럽 뇌회의(European Brain Council)는 600개 이상의 신경질환과 300명의 정신질환이 간질환자 6,500만 명을 포함한 세계 수백만 명에 영향을 미쳤다고 보고했습니다. 게다가 유럽에서는 치매 환자 수가 2022년 1,050만명에서 2050년에는 1,870만명으로 증가할 것으로 예측됩니다. 따라서 신경질환의 유병률 증가는 수요를 자극하고 중추신경계(CNS) 림프종 시장의 성장을 가속할 것으로 예측됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 중추신경계(CNS) 림프종 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 중추신경계(CNS) 림프종 시장 : 성장률 분석
- 세계의 중추신경계(CNS) 림프종 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 중추신경계(CNS) 림프종 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 중추신경계(CNS) 림프종 전체 시장(TAM)
제6장 시장 세분화
- 세계의 중추신경계(CNS) 림프종 시장 : 약제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 단클론 항체
- 화학 치료제
- 코르티코스테로이드
- 세계의 중추신경계(CNS) 림프종 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 화학 치료
- 방사선 치료
- 스테로이드 치료
- 표적 치료
- 세계의 중추신경계(CNS) 림프종 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 클리닉
- 외래 수술 서비스
- 기타 용도
- 세계의 중추신경계(CNS) 림프종 시장 : 단클론 항체 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 항-CD20 단클론 항체
- 항-PD-1 단클론 항체
- 기타 표적 단클론 항체
- 세계의 중추신경계(CNS) 림프종 시장 : 화학 치료제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 알킬화제
- 항대사제
- 토포이소머라제 억제제
- 세계의 중추신경계(CNS) 림프종 시장 : 코르티코스테로이드 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 덱사메타손
- 프레드니솔론
- 메틸프레드니솔론
제7장 지역별/국가별 분석
- 세계의 중추신경계(CNS) 림프종 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 중추신경계(CNS) 림프종 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 중추신경계(CNS) 림프종 시장 : 경쟁 구도
- 중추신경계(CNS) 림프종 시장 : 기업 프로파일
- F. Hoffmann-La Roche Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
- Novartis International AG 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Gilead Sciences Inc.
- Amgen Inc.
- Fresenius SE & Co. KGaA
- Incyte Corporation
- ONO PHARMA USA Inc.
- Kazia Therapeutics Limited
- Simcere Pharmaceutical Group Limited
- Karyopharm Therapeutics Inc.
- Nurix Therapeutics Inc.
- CNS Pharmaceuticals Inc.
- JW Therapeutics
- PentixaPharm Pty Ltd
- Cellectar Biosciences Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 중추신경계(CNS) 림프종 시장(2029년) : 새로운 기회를 제공하는 국가
- 중추신경계(CNS) 림프종 시장(2029년) : 새로운 기회를 제공하는 부문
- 중추신경계(CNS) 림프종 시장(2029년) : 성장 전략
제36장 부록
KTH
Central nervous system (CNS) lymphoma is a rare and aggressive form of lymphoma that originates in the brain or spinal cord. The primary goal of treatment is to target and shrink cancerous cells in the CNS, alleviate symptoms, and improve survival rates through a combination of medications, targeted therapies, and focused high-energy treatments.
The main drugs in the central nervous system (CNS) lymphoma market include monoclonal antibodies, chemotherapeutic agents, and corticosteroids. Monoclonal antibodies are laboratory-created proteins that replicate the immune system's ability to identify and neutralize specific targets, such as cancer cells, viruses, or inflammatory molecules. These treatments are administered through various methods, including chemotherapy, radiation therapy, steroid therapy, and targeted therapy. The market also serves a range of applications, including hospitals, clinics, ambulatory surgical services, and other healthcare settings.
The central nervous system (CNS) lymphoma market research report is one of a series of new reports from The Business Research Company that provides central nervous system (CNS) lymphoma market statistics, including the central nervous system (CNS) lymphoma industry global market size, regional shares, competitors with the central nervous system (CNS) lymphoma market share, detailed central nervous system (CNS) lymphoma market segments, market trends, and opportunities, and any further data you may need to thrive in the central nervous system (CNS) lymphoma industry. This central nervous system (CNS) lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The central nervous system (CNS) lymphoma market size has grown strongly in recent years. It will grow from $1.44 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historical period can be attributed to factors such as increased awareness and diagnosis, a rising incidence of lymphoma, a growing number of clinical trials, increased funding for cancer research, and a greater use of biomarkers for targeted treatments.
The central nervous system (CNS) lymphoma market size is expected to see strong growth in the next few years. It will grow to $1.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be attributed to factors such as the growing adoption of immunotherapy, an increasing focus on targeted treatments, a rising prevalence of CNS lymphoma, improved patient access to healthcare, and government support and initiatives. Key trends during this period include the integration of artificial intelligence in diagnostics, the development of next-generation monoclonal antibodies, a shift toward less invasive treatments, advancements in precision medicine, and innovations in diagnostic technologies.
The increasing incidence of psychological disorders is expected to significantly drive the growth of the central nervous system (CNS) lymphoma market. Psychological disorders, which affect thoughts, emotions, and behaviors, are influenced by factors such as stress, social isolation, economic pressures, genetics, substance abuse, and excessive use of digital technologies. As the prevalence of these disorders rises, it advances neuro-oncology research, which enhances the understanding of brain inflammation, immune system interactions, and the blood-brain barrier. This deeper insight contributes to the development of better treatments for both cancer and mental health conditions. For instance, the National Alliance on Mental Illness reported in 2024 that nearly 600,000 hospitalizations in the U.S. each year are due to psychosis spectrum and mood disorders among individuals aged 18-44. Therefore, the rising incidence of psychological disorders plays a role in propelling growth in the CNS lymphoma market.
The increasing prevalence of neurological disorders is another factor expected to boost the central nervous system (CNS) lymphoma market. Neurological disorders, which affect the brain, spinal cord, and nerves, are becoming more common due to factors such as genetics, infections, trauma, toxins, autoimmune responses, and degenerative processes. CNS lymphoma research contributes significantly to advancing diagnostics and treatments for neurological disorders by improving understanding of brain function, immune response, and neuroinflammation. For example, in April 2022, the European Brain Council reported that over 600 neurological diseases and nearly 300 psychiatric conditions impact millions of people worldwide, including 65 million with epilepsy. Additionally, projections indicate that the number of people in Europe affected by dementia will rise from 10.5 million in 2022 to 18.7 million by 2050. As such, the growing prevalence of neurological disorders is expected to fuel demand and drive the growth of the CNS lymphoma market.
In March 2023, ONO Pharma Inc. received orphan drug designation from the U.S. Food and Drug Administration (FDA) for tirabrutinib (ONO-4059) as a treatment for PCNSL. Currently under investigation in the phase 2 PROSPECT study, tirabrutinib targets critical pathways involved in B-cell proliferation and survival, offering new potential treatment options for B-cell malignancies such as primary CNS lymphoma. This highlights the ongoing efforts to develop innovative therapies to address CNS lymphoma and related neurological conditions.
Major players in the central nervous system (CNS) lymphoma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Incyte Corporation, ONO PHARMA USA Inc., Kazia Therapeutics Limited, Simcere Pharmaceutical Group Limited, Karyopharm Therapeutics Inc., Nurix Therapeutics Inc., CNS Pharmaceuticals Inc., JW Therapeutics, PentixaPharm Pty Ltd, Cellectar Biosciences Inc.
North America was the largest region in the central nervous system (CNS) lymphoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in central nervous system (CNS) lymphoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the central nervous system (CNS) lymphoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The central nervous system (CNS) lymphoma market consists of revenues earned by entities by providing services such as diagnostic service, therapy services, and supportive and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The central nervous system (CNS) lymphoma market also includes sales of drugs, therapy equipment, supportive therapies, and surgical instruments & tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Central Nervous System (CNS) Lymphoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on central nervous system (cns) lymphoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for central nervous system (cns) lymphoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The central nervous system (cns) lymphoma market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Class Of Drugs: Monoclonal antibodies; Chemotherapeutic Agents; Corticosteroids
- 2) By Treatment: Chemotherapy; Radiation Therapy; Steroid Therapy; Targeted Therapy
- 3) By Application: Hospitals; Clinics; Ambulatory Surgical Services; Other Applications
- Subsegments:
- 1) By Monoclonal Antibodies: Anti-CD20 Monoclonal Antibodies; Anti-PD-1 Monoclonal Antibodies; Other Targeted Monoclonal Antibodies
- 2) By Chemotherapeutic Agents: Alkylating Agents; Antimetabolites; Topoisomerase Inhibitors
- 3) By Corticosteroids: Dexamethasone; Prednisolone; Methylprednisolone
- Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.; Novartis International AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Central Nervous System (CNS) Lymphoma Market Characteristics
3. Central Nervous System (CNS) Lymphoma Market Trends And Strategies
4. Central Nervous System (CNS) Lymphoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Central Nervous System (CNS) Lymphoma Growth Analysis And Strategic Analysis Framework
- 5.1. Global Central Nervous System (CNS) Lymphoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Central Nervous System (CNS) Lymphoma Market Growth Rate Analysis
- 5.4. Global Central Nervous System (CNS) Lymphoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Central Nervous System (CNS) Lymphoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Central Nervous System (CNS) Lymphoma Total Addressable Market (TAM)
6. Central Nervous System (CNS) Lymphoma Market Segmentation
- 6.1. Global Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monoclonal antibodies
- Chemotherapeutic Agents
- Corticosteroids
- 6.2. Global Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy
- Radiation Therapy
- Steroid Therapy
- Targeted Therapy
- 6.3. Global Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Ambulatory Surgical Services
- Other Applications
- 6.4. Global Central Nervous System (CNS) Lymphoma Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anti-CD20 Monoclonal Antibodies
- Anti-PD-1 Monoclonal Antibodies
- Other Targeted Monoclonal Antibodies
- 6.5. Global Central Nervous System (CNS) Lymphoma Market, Sub-Segmentation Of Chemotherapeutic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- 6.6. Global Central Nervous System (CNS) Lymphoma Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Dexamethasone
- Prednisolone
- Methylprednisolone
7. Central Nervous System (CNS) Lymphoma Market Regional And Country Analysis
- 7.1. Global Central Nervous System (CNS) Lymphoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Central Nervous System (CNS) Lymphoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Central Nervous System (CNS) Lymphoma Market
- 8.1. Asia-Pacific Central Nervous System (CNS) Lymphoma Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Central Nervous System (CNS) Lymphoma Market
- 9.1. China Central Nervous System (CNS) Lymphoma Market Overview
- 9.2. China Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Central Nervous System (CNS) Lymphoma Market
- 10.1. India Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Central Nervous System (CNS) Lymphoma Market
- 11.1. Japan Central Nervous System (CNS) Lymphoma Market Overview
- 11.2. Japan Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Central Nervous System (CNS) Lymphoma Market
- 12.1. Australia Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Central Nervous System (CNS) Lymphoma Market
- 13.1. Indonesia Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Central Nervous System (CNS) Lymphoma Market
- 14.1. South Korea Central Nervous System (CNS) Lymphoma Market Overview
- 14.2. South Korea Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Central Nervous System (CNS) Lymphoma Market
- 15.1. Western Europe Central Nervous System (CNS) Lymphoma Market Overview
- 15.2. Western Europe Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Central Nervous System (CNS) Lymphoma Market
- 16.1. UK Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Central Nervous System (CNS) Lymphoma Market
- 17.1. Germany Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Central Nervous System (CNS) Lymphoma Market
- 18.1. France Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Central Nervous System (CNS) Lymphoma Market
- 19.1. Italy Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Central Nervous System (CNS) Lymphoma Market
- 20.1. Spain Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Central Nervous System (CNS) Lymphoma Market
- 21.1. Eastern Europe Central Nervous System (CNS) Lymphoma Market Overview
- 21.2. Eastern Europe Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Central Nervous System (CNS) Lymphoma Market
- 22.1. Russia Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Central Nervous System (CNS) Lymphoma Market
- 23.1. North America Central Nervous System (CNS) Lymphoma Market Overview
- 23.2. North America Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Central Nervous System (CNS) Lymphoma Market
- 24.1. USA Central Nervous System (CNS) Lymphoma Market Overview
- 24.2. USA Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Central Nervous System (CNS) Lymphoma Market
- 25.1. Canada Central Nervous System (CNS) Lymphoma Market Overview
- 25.2. Canada Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Central Nervous System (CNS) Lymphoma Market
- 26.1. South America Central Nervous System (CNS) Lymphoma Market Overview
- 26.2. South America Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Central Nervous System (CNS) Lymphoma Market
- 27.1. Brazil Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Central Nervous System (CNS) Lymphoma Market
- 28.1. Middle East Central Nervous System (CNS) Lymphoma Market Overview
- 28.2. Middle East Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Central Nervous System (CNS) Lymphoma Market
- 29.1. Africa Central Nervous System (CNS) Lymphoma Market Overview
- 29.2. Africa Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Central Nervous System (CNS) Lymphoma Market Competitive Landscape And Company Profiles
- 30.1. Central Nervous System (CNS) Lymphoma Market Competitive Landscape
- 30.2. Central Nervous System (CNS) Lymphoma Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
31. Central Nervous System (CNS) Lymphoma Market Other Major And Innovative Companies
- 31.1. Takeda Pharmaceutical Company Limited
- 31.2. Eli Lilly and Company
- 31.3. Gilead Sciences Inc.
- 31.4. Amgen Inc.
- 31.5. Fresenius SE & Co. KGaA
- 31.6. Incyte Corporation
- 31.7. ONO PHARMA USA Inc.
- 31.8. Kazia Therapeutics Limited
- 31.9. Simcere Pharmaceutical Group Limited
- 31.10. Karyopharm Therapeutics Inc.
- 31.11. Nurix Therapeutics Inc.
- 31.12. CNS Pharmaceuticals Inc.
- 31.13. JW Therapeutics
- 31.14. PentixaPharm Pty Ltd
- 31.15. Cellectar Biosciences Inc.
32. Global Central Nervous System (CNS) Lymphoma Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Central Nervous System (CNS) Lymphoma Market
34. Recent Developments In The Central Nervous System (CNS) Lymphoma Market
35. Central Nervous System (CNS) Lymphoma Market High Potential Countries, Segments and Strategies
- 35.1 Central Nervous System (CNS) Lymphoma Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Central Nervous System (CNS) Lymphoma Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Central Nervous System (CNS) Lymphoma Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
